Alice Fracassi

Dr. Alice Fracassi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
GBGiorgio Bogani
Giorgio Bogani
LLLuca Lalli
Luca Lalli
FSFrancesco Sopracordevole
Francesco Sopracordevole
ACAndrea Ciavattini
Andrea Ciavattini
AGAlessandro Ghelardi
Alessandro Ghelardi
VDViolante Di Donato
Violante Di Donato
Background: Cervical dysplasia persistence/recurrence has a great impact on women’s health and quality of life. In this study, we investigated whether a prognostic nomogram may improve risk assessment after primary conization. Methods: This is a retrospective multi-institutional study based on charts of consecutive patients undergoing conization between 1 January 2010 and 31 December 2014. A nomogram assessing the importance of different variables was built. A cohort of patients treated between 1 January 2015 and 30 June 2016 was used to validate the nomogram. Results: A total of 2966 patients undergoing primary conization were analyzed. The median (range) patient age was 40 (18–89) years. At 5-year of follow-up, 6% of patients (175/2966) had developed a persistent/recurrent cervical dysplasia. Median (range) recurrence-free survival was 18 (5–52) months. Diagnosis of CIN3, presence of HR-HPV types, positive endocervical margins, HPV persistence, and the omission of HPV vaccination after conization increased significantly and independently of the risk of developing cervical dysplasia persistence/recurrence. A nomogram weighting the impact of all variables was built with a C-Index of 0.809. A dataset of 549 patients was used to validate the nomogram, with a C-index of 0.809. Conclusions: The present nomogram represents a useful tool for counseling women about their risk of persistence/recurrence after primary conization. HPV vaccination after conization is associated with a reduced risk of CIN2+.

19 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CTChiara Di Tucci
Chiara Di Tucci
GGGiulia Galati
Giulia Galati
GMGiulia Mattei
Giulia Mattei
ACAlessandra Chinè
Alessandra Chinè
AFAlice Fracassi
Alice Fracassi
LMLudovico Muzii
Ludovico Muzii
The incidence of cancer in reproductive-aged women is 7%, but, despite the increased number of cancer cases, advances in early diagnosis and treatment have raised the survival rate. Furthermore, in the last four decades, there has been a rising trend of delaying childbearing. There has been an increasing number of couples referred to Reproductive Medicine Centers for infertility problems after one partner has been treated for cancer. In these cases, the main cause of reduced fertility derives from treatments. In this review, we describe the effects and the risks of chemotherapy, radiotherapy, and surgery in women with cancer, and we will focus on available fertility preservation techniques and their efficacy in terms of success in pregnancy and live birth rates.

1 January 2022 in Archives of Clinical and Medical Case Reports
Verified
Journal Article
Open access
PDF file
FCFabiana Carbone
Fabiana Carbone
GSGIUSI SANTANGELO
GIUSI SANTANGELO
MSMaria Scudo
Maria Scudo
AFAlice Fracassi
Alice Fracassi
GGGabriella Gentile
Gabriella Gentile
GPGiorgia Perniola
Giorgia Perniola
Background: Gestational trophoblastic disease (GTD) is a rare developmental form of proliferative trophoblastic tissue. Scarse literature exists regarding the optimal management of patients with advanced GTD. We report a case of high risk GTD treated with poly-chemotherapy prior to uterine suction curettage. Case: A 29-year-old woman presented high risk GTD. She was treated with three cycles of poly-chemotherapy in another hospital and then she was referred to our emergency room for the surgical management. Conclusion: This case highlights the possibility of conservative treatment of GTD.